marketing news releases corporate philosophy what is hhc compliance message to stakeholders eisai s views on environmental issues integrated report environmental report social contribution activities potential suppliers business performance highlights share information for shareholders financial information presentations integrated report environmental report ir calendar analyst coverage investor kit bonds and ratings ir site map understanding eisai integrated report please click here to vieweisai inc. u.s. website october 13 2016eisai to officially launch chocola bb rich ceramide in stores nationwidejapan s first food with function claims drink containing ceramide drink to counter dry skin october 12 2016preliminary phase ib clinical study results for lenvatinib in combination with pembrolizumab in selected solid tumors presented at esmo 2016october 4 2016exclusive licensing agreement for in house developed monoclonal antibody farletuzumab in latin america concluded with eurofarma laborat rios s.a.october 4 2016launch of uritos tablets for overactive bladder in thailandoctober 4 2016belviq xr a new once daily formulation of belviq for chronic weight management now available in the united states october 12 2016access to medicines current distribution status of dec tablets for endemic countries august 30 2016ir integrated report 2016 august 9 2016commitment & passion for hhc eisai provides internship to medical student from indonesia august 4 2016ir first quarter financial results explanation for the fiscal year ending march 31 2017 material webcast august 4 2016corporate governance report noticejune 20 2016notice of shareholder voting results for the 104th ordinary general meeting of shareholdersjune 17 2016notice of resolution of the 104th ordinary general meeting of shareholders